Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
A look back at 2016's recurring bills reveals a stark financial truth: small, consistent savings on expenses like cable, cell plans, or insurance, when invested, could have yielded a significant nest egg by today.
While analyst price targets often paint a rosy picture, a deeper look reveals which recommendations are backed by solid business trends and which may be overly optimistic. We examine one fintech disruptor and one industrial stalwart favored by the Street, alongside a retailer facing significant headwinds.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
A bus carrying Ukrainian miners home from their shift was struck by Russian drones in a coordinated attack, leaving at least 15 dead and 7 wounded. The assault, condemned as an act of terrorism, marks one of the deadliest single incidents for the energy company DTEK since the invasion began.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
TreeHouse Foods (THS) shares have rebounded sharply over the past three months, gaining 31%, even as the company reports significant annual losses. This divergence between short-term momentum and long-term fundamentals is prompting a fresh debate on valuation and the path to profitability for the private-label food manufacturer.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Japanese apparel retailer Shimamura (TSE:8227) has completed a massive share repurchase program and reshuffled its executive team in a concentrated two-day move, signaling a strategic pivot to boost per-share metrics and long-term value.
AutoNation's move to permanently eliminate 3,500 positions marks a decisive shift in its operational strategy, raising critical questions for investors about cost efficiency, debt sustainability, and the long-term resilience of the auto retail business model.
In the aftermath of the devastating '10/10' market crash of 2025, Binance finds its dominance and trust metrics under a microscope. While the exchange compensated users and maintains its user base, questions about systemic risk and centralization linger, shaping the post-crash narrative.
A sharp weekend sell-off pushed Bitcoin below a key cost basis for major holders, liquidating leveraged bets and rattling a market already on edge from cooling ETF inflows and heightened leverage.
While major indices grapple with uncertainty, a search for value is leading some investors to overlooked companies with strong fundamentals. We examine three such firms from Taiwan and Japan that are posting impressive growth despite sector headwinds.
A quiet crisis is eroding the foundation of U.S. economic decision-making. As key federal data agencies face budget cuts, political pressure, and operational challenges, the resulting information gap could leave policymakers and businesses 'flying blind,' increasing the risks of policy missteps, deeper recessions, and prolonged unemployment.
LinkedIn co-founder Reid Hoffman argues that AI-native startups, by building custom solutions for precise problems, are enabling tiny teams to achieve output once requiring ten times the headcount, fundamentally reshaping productivity and competition.
Satellite communications provider Viasat (VSAT) saw its shares hit a new 52-week peak of $46.49, capping a remarkable 12-month rally. The surge follows a significant price target upgrade from Morgan Stanley and the successful launch of a key global network for government clients.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
One of Ethereum's largest holders faces a potential multi-billion dollar liquidation as prices slide, prompting urgent deleveraging moves that could ripple across crypto markets.
Solana's leading DEX aggregator Jupiter announces a landmark integration with prediction market giant Polymarket, alongside securing a $35 million strategic investment from ParaFi Capital, signaling a major push into on-chain forecasting.
